Markets:

Overview

News

Currencies

International

Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

3.430 +0.230 (+7.19%)

Streaming Delayed Price Updated: 12:13 PM EDT, Apr 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Editas Medicine Announces Pricing of Offering of Common Stock

June 14, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Announces Offering of Common Stock

June 14, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

What 6 Analyst Ratings Have To Say About Editas Medicine ↗

June 13, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 13, 2023 ↗

June 13, 2023

Via Benzinga

Editas Medicine's Return On Capital Employed Insights ↗

May 19, 2023

Via Benzinga

5 Stocks to Buy With Explosive 500% Potential ↗

June 12, 2023

Take advantage of a bullish change in investor sentiment with these five stocks to buy for 500% upside potential.

Via InvestorPlace

Editas' Gene Editing Treatment Shows Initial Safety, Efficacy In Patients With Rare Blood Disorders ↗

June 09, 2023

Editas Medicine Inc (NASDAQ: EDIT) annou

Via Benzinga

Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial

June 09, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today? ↗

June 06, 2023

Gene editing stocks are up today on news that Editas Medicine will present clinical data on June 12. Here's what this means for the sector.

Via InvestorPlace

6 Analysts Have This to Say About Editas Medicine ↗

May 08, 2023

Via Benzinga

Editas Medicine: Q1 Earnings Insights ↗

May 05, 2023

Via Benzinga

Preview: Editas Medicine's Earnings ↗

May 04, 2023

Via Benzinga

2 Stocks Under $15 Per Share to Consider ↗

April 16, 2023

Anyone can get in on the stock market at these prices.

Via The Motley Fool

Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia

June 06, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

Genprex (NASDAQ: GNPX) Releases New Patient Video Interview Describing Positive Experience in Clinical Trial ↗

June 01, 2023

A clinical-stage gene therapy company is making splashes in the medical world. Genprex, Inc. (NASDAQ: GNPX) is developing potentially life-changing therapies for patients with cancer and diabetes that...

Via Benzinga

7 Short-Squeeze Stocks Set for a May Rally ↗

May 22, 2023

While targeting the best short-squeeze stocks to buy now can be incredibly treacherous, they may also yield robust returns.

Via InvestorPlace

Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You? ↗

May 21, 2023

It's facing a few issues that are practically guaranteed to affect shareholder returns.

Via The Motley Fool

Editas Medicine Reports Inducement Grant to New Chief Financial Officer

May 18, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer

May 16, 2023

Michelle Robertson to remain with Company until August 16, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

ONEOK, PacWest Bancorp And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

May 15, 2023

U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress

May 11, 2023

Company-sponsored webinar to be announced

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Announces First Quarter 2023 Results and Business Updates

May 05, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Announces Publication in Nature Biotechnology of Comprehensive SLEEK Gene Editing Technology Data

May 01, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

Earnings Scheduled For May 5, 2023 ↗

May 05, 2023

Companies Reporting Before The Bell • CNH Industrial (NYSE:CNHI) is estimated to report quarterly earnings at $0.32 per share on revenue of $5.08 billion.

Via Benzinga

Editas Medicine Announces First Quarter 2023 Results Conference Call and Upcoming Investor Events

May 01, 2023

From Editas Medicine, Inc.

Via GlobeNewswire

The 3 Most Promising Gene Editing Stocks to Buy in 2023 ↗

April 28, 2023

Intellia, Beam, and Editas are using gene editing to cure incurable diseases. These are three gene editing stocks you'll want to invest in.

Via InvestorPlace

Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease

April 27, 2023

On track to provide clinical update for RUBY trial by mid-2023 and dose 20 total patients by year-end

From Editas Medicine, Inc.

Via GlobeNewswire

Why Shares of Editas Medicine Rose Monday ↗

April 17, 2023

The company is benefiting from positive news affecting other gene-editing stocks.

Via The Motley Fool

Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

April 17, 2023

Gainers ContraFect Corporation (NASDAQ: CFRX) shares surged 213% to $2.82.

Via Benzinga

Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today? ↗

April 13, 2023

While CRSPR stock captured the spotlight for potentially encouraging drug data, the news lifted other gene-editing stocks.

Via InvestorPlace

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.